Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

12.89
BATS BZX Real-Time Price
As of 1:49pm ET
 -0.425 / -3.19%
Today’s Change
8.31
Today|||52-Week Range
32.74
-11.26%
Year-to-Date
Jeff Ubben Buys 1, Sells 1 in 1st Quarter
11:15am / GuruFocus News - Paid Partner Content
5 Things You Must Know Before the Market Opens Friday
May 19 / TheStreet.com - Paid Partner Content
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
May 23 / GuruFocus News - Paid Partner Content
Bill Ackman Details Missteps with Valeant Investment
May 18 / TheStreet.com - Paid Partner Content
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
May 22 / Zacks.com - Paid Partner Content
Francis Chou Buys Pharmaceutical Stocks, Including Valeant
May 17 / GuruFocus News - Paid Partner Content
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
May 19 / GuruFocus News - Paid Partner Content
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
May 17 / GuruFocus News - Paid Partner Content
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
May 19 / Zacks.com - Paid Partner Content
Allergan's Irritable Bowel Drug Viberzi Approved in Canada
May 17 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close13.31
Today’s open13.25
Day’s range12.75 - 13.33
Volume567,828
Average volume (3 months)21,304,014
Market cap$4.5B
Dividend yield--
Data as of 1:49pm ET, 05/24/2017

Growth & Valuation

Earnings growth (last year)-716.47%
Earnings growth (this year)-32.57%
Earnings growth (next 5 years)-1.55%
Revenue growth (last year)-7.39%
P/E ratioNM
Price/Sales0.52
Price/Book1.47

Competitors

 Today’s
change
Today’s
% change
TAROTaro Pharmaceutical ...-0.77-0.71%
CTLTCatalent Inc+0.84+2.42%
PTHNPatheon NV+0.04+0.12%
AKRXAkorn Inc0.000.00%
Data as of 1:49pm ET, 05/24/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$0.96
Annual revenue (last year)$9.7B
Annual profit (last year)-$2.4B
Net profit margin-24.90%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts